Daniela Guadalupe Valencia-Pérez Rea

Dr. Daniela Guadalupe Valencia-Pérez Rea


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IFIngrid Fricke-Galindo
Ingrid Fricke-Galindo
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
DPDaniel I. Ponce-Aguilar
Daniel I. Ponce-Aguilar
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Leslie Chavez-GalanLeslie Chavez-Galan
Leslie Chavez-Galan
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
This paper assesses the association of the insertion/deletion ACE (angiotensin-converting enzyme) variant (rs1799752 I/D) and the serum ACE activity with the severity of COVID-19 as well as its impact on post-COVID-19, and we compare these associations with those for patients with non-COVID-19 respiratory disorders. We studied 1252 patients with COVID-19, 104 subjects recovered from COVID-19, and 74 patients hospitalized with a respiratory disease different from COVID-19. The rs1799752 ACE variant was assessed using TaqMan® Assays. The serum ACE activity was determined using a colorimetric assay. The DD genotype was related to risk for invasive mechanical ventilation (IMV) requirement as an indicator of COVID-19 severity when compared to the frequencies of II + ID genotypes (p = 0.025, OR = 1.428, 95% CI = 1.046–1.949). In addition, this genotype was significantly higher in COVID-19 and post-COVID-19 groups than in the non-COVID-19 subjects. The serum ACE activity levels were lower in the COVID-19 group (22.30 U/L (13.84–32.23 U/L)), which was followed by the non-COVID-19 (27.94 U/L (20.32–53.36 U/L)) and post-COVID-19 subjects (50.00 U/L (42.16–62.25 U/L)). The DD genotype of the rs1799752 ACE variant was associated with the IMV requirement in patients with COVID-19, and low serum ACE activity levels could be related to patients with severe disease.

Verified
Journal Article
Open access
PDF file
SCSalvador GARCIA García Carmona
Salvador GARCIA García Carmona
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
IAItzel Abigail Veronica Aguilar
Itzel Abigail Veronica Aguilar
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
Leslie Chavez-GalanLeslie Chavez-Galan
Leslie Chavez-Galan
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Background: Genetic susceptibility to infectious diseases is partly due to the variation in the human genome, and COVID-19 is not the exception. This study aimed to identify whether risk alleles of known genes linked with emphysema (SERPINA1) and pulmonary fibrosis (MUC5B) are associated with severe COVID-19, and whether plasma mucin 5B differs according to patients’ outcomes. Materials and methods: We included 1258 Mexican subjects diagnosed with COVID-19. We genotyped rs2892474 and rs17580 of the SERPINA1 gene and rs35705950 of MUC5B. Based on the rs35705950 genotypes, mucin 5B plasma protein levels were quantified. Results: Homozygous for the risk alleles of the three polymorphisms were found in less than 5% of the study population, but no statistically significant difference in the genotype or allele association analysis. At the protein level, non-survivors carrying one or two copies of the risk allele rs35705950 in MUC5B (GT + TT) had lower levels of mucin 5B compared to the survivors (0.0 vs. 0.17 ng/mL, p = 0.0013). Conclusion: The polymorphisms rs28929474 and rs17580 of SERPINA1 and rs35705950 of MUC5B are not associated with the risk of severe COVID-19 in the Mexican population. COVID-19 survivor patients bearing one or two copies of the rs35705950 risk allele have higher plasma levels of mucin 5B.

Verified
Journal Article
Open access
PDF file
DRDaniela Guadalupe Valencia-Pérez Rea
Daniela Guadalupe Valencia-Pérez Rea
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
IFIngrid Fricke-Galindo
Ingrid Fricke-Galindo
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
Leslie Chavez-GalanLeslie Chavez-Galan
Leslie Chavez-Galan
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Tobacco smoking is the leading risk factor for many respiratory diseases. Several genes are associated with nicotine addiction, such as CHRNA5 and ADAM33. This research aims to evaluate the association of the polymorphisms rs16969968 (CHRNA5) and rs3918396 (ADAM33) in patients who developed severe COVID-19. We included 917 COVID-19 patients hospitalized with critical disease and oxygenation impairment. They were divided into two groups, tobacco-smoking (n = 257) and non-smoker (n = 660) patients. The genotype and allele frequencies of two single nucleotide variants, the rs16969968 (CHRNA5) and rs3918396 (ADAM33), were evaluated. The rs3918396 in ADAM33 does not show a significative association. We analyzed the study population according to the rs16969968 genotype (GA + AA, n = 180, and GG, n = 737). The erythrocyte sedimentation rate (ESR) shows statistical differences; the GA + AA group had higher values than the GG group (p = 0.038, 32 vs. 26 mm/h, respectively). The smoking patients and GA or AA genotype carriers had a high positive correlation (p < 0.001, rho = 0.753) between fibrinogen and C-reactive protein. COVID-19 patients and smokers carriers of one or two copies of the risk allele (rs16969968/A) have high ESR and a positive correlation between fibrinogen and C-reactive protein.

Verified
Journal Article
Open access
PDF file
OROreth Montero Ruíz
Oreth Montero Ruíz
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
DRDaniela Guadalupe Valencia-Pérez Rea
Daniela Guadalupe Valencia-Pérez Rea
GRGibran E. Rueda-Munive
Gibran E. Rueda-Munive
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Background: This study was conducted to identify genetic risk variants associated with nicotine addiction in the CHRNA5, HTR2A, DRD4, and CYP2A6 genes among electronic cigarette users who also smoke combustible cigarettes (dual users), and to assess potential genotoxic and cytotoxic damage in the oral mucosal cells of the study population. Methods: We included dual e-cig users (ECIG, n = 70), combustible cigarette smokers (CCU, n = 24), and non-smokers and non-e-cig users (NS, n = 110). Genetic variants in CHRNA5, HTR2A, DRD4, and CYP2A6 were genotyped. Micronucleus analysis was performed on oral mucosal cells to detect cellular abnormalities. Results: The ECIG group demonstrated greater nicotine addiction on the Fagerström Test for Nicotine Dependence (FTND, 5.5 vs. 1, p = 0.023). Salivary cotinine levels were significantly higher in the ECIG group compared to the CCU group (39 vs. 12 ng/mL, p < 0.001). The carriers of the A allele (rs16969968/CHRNA5) had higher FTND scores, carriers of the C allele (rs1800955/DRD4) used electronic cigarettes more frequently each day, and carriers of the T allele (rs4105144/CYP2A6) started using nicotine products at a younger age. The number of micronuclei and cellular abnormalities in the oral mucosa was higher in the ECIG and CCU groups compared to the NS group. Conclusions: Salivary cotinine levels and FTND are higher in dual e-cigarette users than in combustible cigarette users. Dual users exhibit risk alleles in the CHRNA5, DRD4, and CYP2A6 genes, which are associated with traits linked to increased nicotine addiction. Dual e-cigarette use poses comparable genotoxic risks to combustible smoking.